Investigational Drug Information for Entolimod
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
What is the drug development status for Entolimod?
Entolimod is an investigational drug.
There have been 6 clinical trials for Entolimod.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2015.
The most common disease conditions in clinical trials are Nasopharyngeal Neoplasms, Prostatic Neoplasms, and Carcinoma. The leading clinical trial sponsors are Cleveland BioLabs, Inc., National Cancer Institute (NCI), and Roswell Park Cancer Institute.
There are two US patents protecting this investigational drug and three international patents.
Summary for Entolimod
| US Patents | 2 |
| International Patents | 3 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2015-11-01) |
| Vendors | 0 |
Recent Clinical Trials for Entolimod
| Title | Sponsor | Phase |
|---|---|---|
| Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination | Genome Protection, Inc | Phase 2 |
| Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination | Mayo Clinic | Phase 2 |
| Entolimod, an Adjuvant for Vaccine Augmentation | Baylor College of Medicine | Early Phase 1 |
Clinical Trial Summary for Entolimod
Top disease conditions for Entolimod
Top clinical trial sponsors for Entolimod
US Patents for Entolimod
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Entolimod | ⤷ Sign Up | Methods and compositions for the treatment of radiation-related disorders | CLEVELAND BIOLABS, INC. (Buffalo, NY) | ⤷ Sign Up |
| Entolimod | ⤷ Sign Up | Methods and compositions for the treatment of radiation-related disorders | Cleveland BioLabs, Inc. (Buffalo, NY) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Entolimod
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Entolimod | European Patent Office | EP3206708 | 2034-10-16 | ⤷ Sign Up |
| Entolimod | Israel | IL251736 | 2034-10-16 | ⤷ Sign Up |
| Entolimod | World Intellectual Property Organization (WIPO) | WO2016109002 | 2034-10-16 | ⤷ Sign Up |
| Entolimod | European Patent Office | EP3206708 | 2034-10-16 | ⤷ Sign Up |
| Entolimod | Israel | IL251736 | 2034-10-16 | ⤷ Sign Up |
| Entolimod | World Intellectual Property Organization (WIPO) | WO2016109002 | 2034-10-16 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
